Navigation Links
Scientists develop method that ensures safe research on deadly flu viruses
Date:8/12/2013

A new strategy that dismantles a viral genome in human lung cells will ensure safe research on deadly strains of influenza, say researchers from the Icahn School of Medicine at Mount Sinai.

Details of their "molecular biocontainment" approach, designed to prevent effective transmission of these viruses to humans, are published in Nature Biotechnology.

The strategy they developed and tested will enable healthy molecules in human lung cells to latch on to these viruses and cut the bugs up before they have a chance to infect the human host.

Findings from the study, led by Benjamin tenOever and Adolfo Garcia-Sastre, both Fishberg Professors in the Department of Medicine and Department of Microbiology at Mount Sinai, should resolve concerns that led in 2012 to a worldwide, yearlong voluntary moratorium on research into the deadly H5N1 bird flu.

The ban came after several scientific teams successfully altered the H5N1 viral genome to enable airborne transmission of the bird flu between ferrets mammals considered a good research model for humans. The public health concern was that altered H5N1 could escape the lab, infect and spread among humans, producing a global pandemic.

"The question last year was whether the risk of altered bird flu escaping laboratories justified the science aimed at understanding the transmission of these viruses. With our method, the possibility of human transmission is no longer a concern," says Dr. tenOever.

H5N1 normally spreads between poultry and wild birds. It can be transmitted from birds to humans, with difficulty, and has only rarely been passed between people. It is lethal to humans. Since 2003, it has killed 360 people out of 610 people infected.

The researchers say the approach they developed works for all influenza A viruses, which includes H5N1, and potentially with other highly pathogenic RNA viruses, including Ebola and SARS.

Dr. tenOever is known internationally for his work on using microRNAs (miRNAs) small noncoding RNA molecules that help regulate gene expression to help the body fight off viral pathogens. He has created a strategy that mimics the system plants use to destroy invading viruses.

"When a plant recognizes viral material, it creates a small inhibitory RNA (siRNA) that latches on to the virus and cleaves it," says Dr. tenOever. Human cells also have small RNAs in the form of miRNAs, but they are used to maintain cell health not to fight a virus. Drs. tenOever and Garcia-Sastre along with scientists from the University of Maryland's Department of Veterinary Medicine discovered that if they alter a viral genome by adding a binding site for a miRNA found in human cells, that molecule morphs into a plant-like attacker. It latches on to the virus and destroys it in the same way plant siRNAs do.

In this study, the scientists discovered a specific miRNA (miR-192) that is found in human and mouse lung cells, but not in the lungs of ferrets. They added multiple binding sites for miR-192 on to the H5N1 genome, and demonstrated in mice that, upon contact, lung cells destroyed the virus. They then demonstrated that H5N1 transmission between ferrets was not decreased when altered virus was used. The researchers also showed the approach works with other influenza A viruses.

"It is clear that we can apply this technology to any virus," Dr. tenOever says. "The only requirements are that we need a miRNA that is present in humans, but not in the model system where we want to study the virus, such as in ferrets. We also need a viral genome that permits insertion of miRNA target sites."

And once a virus is altered to contain the miRNA target sites, it can replicate ad infinitum for research in laboratories worldwide, Dr. tenOever says. "There is no need to continually go back to the drawing board," he says.

In January, a handful of scientists in nine nations resumed their research on H5N1, using standard biocontainment procedures. Drs. tenOever and Garcia-Sastre believe that adding this molecular biocontainment strategy to their research should relieve any public concern pertaining to this research.


'/>"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related biology news :

1. Neuroscientists identify protein linked to Alzheimers-like afflictions
2. Illinois scientists put cancer-fighting power back into frozen broccoli
3. Scientists learn how soy foods protect against colon cancer
4. Wistar scientists decipher structure of NatA, an enzyme complex that modifies most human proteins
5. Scientists uncover secrets of starfishs bizarre feeding mechanism
6. Geoscientists unearth mineral-making secrets potentially useful for new technologies
7. Scientists discover a molecular switch in cancers of the testis and ovary
8. Scientists at Mainz University decode mechanisms of cell orientation in the brain
9. Scientists from Mainz and Antananarivo describe Lavasoa Dwarf Lemur as new primate species
10. Neuroscience symposium bringing top scientists to Louisville, Aug. 1-2
11. University of Alberta scientists get dirty at the Robson Glacier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... by 2021 from $8.3 billion in 2016 at a ... to 2021. Report Includes - An overview of ... market trends, with data from 2015 and 2016, and ... - Segmentation of the market on the basis of ...
(Date:2/3/2017)... SAN ANTONIO , Feb. 3, 2017  Texas Biomedical ... Dr. Larry Schlesinger as the Institute,s ... of Texas Biomed effective May 31, 2017. He is currently ... and Director of the Center for Microbial Interface Biology at ... Dr. Schlesinger as the new President and CEO of Texas ...
(Date:2/1/2017)... 2017 IDTechEx Research, a leading provider of ... the availability of a new report, Sensors for Robotics: Technologies, ... Reading ... ... Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... 24, 2017 Symic Bio, a biopharmaceutical company ... category of therapeutics, announced today the completion of enrollment ... artery disease. The trial will evaluate the safety and ... the reduction of restenosis following angioplasty. ... for SB-030," said Nathan Bachtell , M.D., Chief ...
(Date:2/24/2017)... Blood Corporation (NYSE: CO ) ("CCBC" or ... laboratory testing, hematopoietic stem cell processing and stem cell ... the third quarter and first nine months of fiscal ... Quarter of Fiscal 2017 Highlights Revenues ... 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... 23, 2017 China Biologic Products, Inc. (NASDAQ: CBPO) ... biopharmaceutical company in China, today announced its financial results for ... Fourth Quarter 2016 Financial Highlights ... 21.7% in RMB terms, or increased by 13.6% in USD ... quarter of 2015. Gross profit increased by ...
(Date:2/24/2017)... 24, 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), ... a Key Opinion Leader event to highlight new clinical ... poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium ... will be held in-person and via live webcast on ... AM PST at the Lotte New York Palace Hotel ...
Breaking Biology Technology: